HIV阳性晚期非鳞NSCLC一线卡铂联合培美曲塞的II期CHIVA试验
IFCT-1001 CHIVA是一项多中心II期试验,评估HIV阳性晚期非鳞非小细胞肺癌患者一线卡铂联合培美曲塞诱导后培美曲塞维持治疗的可行性、疗效与安全性。61例入组患者12周疾病控制率为50.8%(95%CI 38.3-63.4),中位无进展生存期3.5个月、总生存期7.6个月,方案总体可耐受但血液学毒性常见。
要点
- 12周疾病控制率50.8%,达到预设≥30%的主要目标
- 体能状态0-1分者中位总生存期可达11.9个月
- 3-4级中性粒细胞减少发生率53.8%,需关注骨髓抑制
核心结论
- 在HIV阳性晚期非鳞NSCLC患者中,四周期卡铂联合培美曲塞诱导后培美曲塞维持治疗有效且耐受性尚可。
- 研究者建议后续进一步评估卡铂联合培美曲塞与免疫治疗的联合策略。
研究设计与样本
- 多中心II期试验,入组61例HIV阳性晚期非鳞非小细胞肺癌患者。
- 给予四周期卡铂联合培美曲塞诱导,随后对体能状态ECOG≤2者行培美曲塞维持治疗。
- 主要目标为12周后疾病控制率≥30%。
主要发现
- 12周疾病控制率为50.8%(95%CI 38.3-63.4),部分缓解率21.3%。
- 中位无进展生存期3.5个月(95%CI 2.7-4.4),中位总生存期7.6个月(95%CI 5.7-12.8)。
- 体能状态0-1分者中位无进展生存期4.3个月(95%CI 3.1-5.2),中位总生存期11.9个月(95%CI 6.4-14.3)。
- 诱导期3-4级血液学毒性:中性粒细胞减少53.8%、血小板减少35.0%、贫血30.0%。
- 报告2例治疗相关败血症死亡,未发生机会性感染。
关键数值与推荐
- 疾病控制率主要目标阈值为12周时≥30%。
- 49例(80%)体能状态为0-1分,19例(31%)存在脑转移。
- 中位CD4淋巴细胞计数418 cells·µL-1(范围18-1230),中位CD4最低值169.5 cells·µL-1(范围1-822)。
- 48例(80%)病毒学控制;38例(62%)完成四周期诱导,31例(51%)开始培美曲塞维持(中位4.1周期,范围1-19)。
临床怎么用
- 对HIV阳性晚期非鳞NSCLC患者,可考虑卡铂联合培美曲塞诱导后培美曲塞维持作为一线方案。
- 治疗期间需密切监测血液学毒性,尤其是中性粒细胞减少和血小板减少。
- 体能状态较好的患者可能获得更长生存获益,治疗决策应结合体能状态评估。
局限性
- 为单臂II期试验,缺乏随机对照,结论需更大样本验证。
- 未纳入免疫治疗联合方案,无法评估与免疫治疗联合的效果。
- HIV感染相关因素(如CD4计数、病毒学控制)对疗效的影响未设对照分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HIV infection is an exclusion criterion in lung cancer trials. This multicentre phase II trial aimed to assess feasibility, efficacy and safety of first-line carboplatin plus pemetrexed (CaP) followed by pemetrexed (P) maintenance in people living with HIV (PLHIV) with advanced non-squamous non-small cell lung cancer (NS-NSCLC).Four cycles of CaP were followed by P-maintenance therapy in patients with Eastern Cooperative Oncology Group performance status ≤2. The primary objective was a disease control rate (DCR) ≥30% after 12 weeks.Of the 61 PLHIV enrolled, 49 (80%) had a performance status of 0-1, and 19 (31%) had brain metastases. Median CD4 lymphocyte count was 418 cells·µL-1 (range 18-1230), median CD4 lymphocyte nadir was 169.5 cells·µL-1 (1-822); 48 (80%) patients were virologically controlled. Four-cycle inductions were achieved by 38 (62%) patients, and 31 (51%) started P-maintenance (median of 4.1 cycles (range 1-19)). The 12-week DCR was 50.8% (95% CI 38.3-63.4) and partial response rate 21.3%. Median progression-free survival and overall survival were 3.5 (95% CI 2.7-4.4) and 7.6 months (5.7-12.8), respectively. Patients with a performance status of 0-1 had the longest median progression-free survival (4.3 months, 95% CI 3.1-5.2) and overall survival (11.9 months, 95% CI 6.4-14.3). During induction, CaP doublet was well tolerated apart from grade 3-4 haematological toxicities (neutropenia 53.8%; thrombocytopenia 35.0%; anaemia 30.0%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced.In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.
引用
- Lavole A, Greillier L, Mazières J, et al. First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial. Eur Respir J. 2020. PMID: 32444410. doi:10.1183/13993003.02066-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。